Telemedicine in Outpatient Covid-19 Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

607 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-09-18

Study Completion Date

2023-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Covid-19, a commonly severe respiratory tract infection caused by the SARS-CoV2 Coronavirus, poses an increasing threat to individual health and health care systems. The individual disease course ranges from mild to life threatening, the pandemic spread leads to a shortage of health care resources including intensive care availability. It should be the overarching goal to allocate sparse health care resources to those most at need and to simultaneously avoid unnecessary blocking of resources by clinically unjustified hospitalizations.

Individuals with preexisting cardiovascular conditions are at the highest risk of health deterioration, even at younger age. Objective criteria for hospitalization are not immediately available in a outpatient settings. Hence, hospitalization and emergency medical contact is often triggered by subjectively interpreted symptoms. The goal of this project is thus to improve the availability of objective measurements in the outpatient setting by means of an innovative, smartwatch mediated telemedicine approach.

To achieve this goal, the investigators will conduct a randomized clinical trial comparing a smartwatch based telemedicine intervention with standard of care. The intervention group will receive regular objective measurements of heart rate, ECG, and SpO2 and will get access to a 24/7 medical care hotline for consultation. The investigators hypothesize that the intervention group will benefit by a significant reduction in unnecessary hospitalizations and unplanned emergency medicine contacts.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development and Validation of a Telemonitoring System for High-risk Cardiovascular Patients

NCT05485532

Cardiovascular Diseases

ACTIVE_NOT_RECRUITING

Clinical Performance of Withings Move ECG Software for Atrial Fibrillation Detection

NCT04493749

Atrial Fibrillation

UNKNOWN

CoronaWatch - Early Detection of Cardiovascular Risks in COVID-19 Via SmartWatch

NCT04376853

COVID-19

COMPLETED

COVID-19 Surveillance Based on Smart Wearable Device

NCT04459637

COVID-19

COMPLETED

Remote Monitoring Use In Cases Of Suspected COVID-19 (Coronavirus)

NCT04337489

Coronavirus

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid-19 Cardiovascular Risk Factor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Telemedicine Care

Patients receive assessment at baseline and at 30 day follow up. Patient receive a smart watch capeable of recording SpO2, ECG, and heart rate. Patients also receive access to 24/7 medical hotline for telemedical care. All public services of the health care system remain available.

Group Type EXPERIMENTAL

Withings ScanWatch

Intervention Type DEVICE

The smart watch is capable of recording SpO2, ECG, and heart rate.

Control

Patients receive assessment at baseline and at 30 day follow up. Patient have access to all services of the health care system, but do not receive a smart watch or medical hotline access.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Withings ScanWatch

The smart watch is capable of recording SpO2, ECG, and heart rate.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed SARS-CoV2 infection and clinical Covid-19 disease
* age ≥18 years
* Presence of ≥1 relevan cardiovascular condition, defined as (or):

* atrial fibrillation
* systolic or diastolic heart failure
* LV ejection fraction \<50%
* coronary artery disease with past PCI or CABG
* Past myocardial infarction
* diabetes mellitus
* arterial hypertension (treated or untreated)
* active smoking
* chronic obstructive lung disease
* obesity (BMI ≥30kg/m2)
* availability of smartphone and sufficient internet connectivity at home
* ability to use smartwatch
* informed consent to study participation and data protection concept